**Supplemental Material 1.** Risk of the lung cancer associated with ARB compared with CCB, BB, DI, and ACEI

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Group | Subjects N1 | Lung cancer cases N1 | HR (95% CI)2 | RD (95% CI)3 |
| **Cohort after IPTW**(N= 59,009) |
|  CCB | 38,395 | 357 | 1.00 |  |
|  ARB | 20,614 | 108 | 0.75 (0.59, 0.96) | -3.6 (-5.7, -1.5) |
|  |  |  |  |  |
| **Cohort after IPTW** (N= 44,790) |
|  BB | 13,665 | 130 | 1.00 |  |
|  ARB | 31,125 | 152 | 0.77 (0.59, 0.99) | -2.8 (-5.3, -0.4) |
|  |  |  |  |  |
| **Cohort after IPTW** (N= 26,840) |
|  DI | 10,299 | 117 | 1.00 |  |
|  ARB | 16,541 | 89 | 0.72 (0.51, 1.04) | -2.1 (-5.2, 0.9) |
|  |  |  |  |  |
| **Cohort after IPTW** (N= 41,290) |
|  ACEI | 6,966 | 71 | 1.00 |  |
|  ARB | 34,324 | 182 | 0.79 (0.59, 1.05) | -2.4 (-5.6, 0.7) |

The weights are recalculated in each cohort.

1 The number of subjects and case are weighted number rounded at first decimal place

2 Adjusted by inverse probability of treatment weighting

3Rate difference = Difference between weighted incidence rate of each group (per 10,000 person-years)

IPTW, inverse probability treatment weighting; ARB, angiotensin II receptor blockers; CCB, calcium channel blockers; BB, beta blockers; DI, diuretics; ACEI, angiotensin converting enzyme inhibitors